MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
SNWV stock logo

SNWV

SANUWAVE Health, Inc.

$
 (%)
[ms_data_label text=’Delayed data’]
Exchange:  NASDAQ
Market Cap:  
Shares Outstanding:  1.008M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Medical – Devices
   
CEO:  Morgan C. Frank
Full Time Employees:  46
Address: 
3360 Martin Farm Road
Suwanee
GA
30024
US
Website:  https://www.sanuwave.com
SANUWAVE Health, Inc., a shock wave technology company, researches, develops, and commercializes noninvasive, high-energy, and acoustic shock waves for regenerative medicine and other applications in the United States and internationally. Its shockwaves are used to produce a biological response resulting in the body healing itself through the repair and regeneration of tissue, musculoskeletal, and vascular structures. The company’s lead regenerative product is the dermaPACE device for treating diabetic foot ulcers. Its portfolio of healthcare products and product candidates activate biologic signaling and angiogenic responses, including new vascularization and microcirculatory improvement, which helps to restore the body’s normal healing processes and regeneration. The company also focuses on applying its Pulsed Acoustic Cellular Expression technology in wound healing, orthopedic, plastic/cosmetic, and cardiac conditions. In addition, it offers UltraMIST, non-contact and non-thermal ultrasound therapy device used to treat diabetic foot ulcers, pressure ulcers, venous leg ulcers, deep tissue pressure injuries, and surgical wounds; and orthoPACE system to treat tendinopathies and acute and nonunion fractures. The company was founded in 2005 and is headquartered in Suwanee, Georgia.

Click to read more…

Revenue Segmentation

MARKETSnap
MARKETSnap

Log in to continue

Log in to see the complete revenue and geographic breakdown.

Login — it's free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

Full text

Earnings transcript

Read the complete earnings call transcript.

AI summary

Key takeaways

Short, structured highlights from the call so you can focus on what matters.

2025/05/09 — Q1 quarter 2025

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue20,39832,63444,051
Gross Profit14,36324,55033,089
EBITDA-9,152-16,5636,228
Operating Income-5405,4174,945
Net Income-25,807-31,37211,813

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets22,41630,11937,343
Total Liabilities65,59442,83635,724
Total Stockholders Equity-43,178-12,7171,619
Total Debt31,94425,49622,971
Cash and Cash Equivalents1,79710,23711,959

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow-4,5382,4553,876
Capital Expenditure0-490-1,942
Free Cash Flow-4,5381,9651,934
Net Income-25,807-12,7480
Net Change in Cash6448,4401,722

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2031Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)27,031.790Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)27,507.209Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)27,269.500Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)-8,409.184Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)-8,263.845Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)-8,336.515Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)-34,445.422Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)-33,673.409Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)-34,059.416Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)24,708.685Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)25,143.246Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)24,925.966Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)-3.750Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)-3.710Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)-3.790Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
3.07
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
11.4
?Enterprise Value
 (TTM)
: 
146.199M  ?EV/FCF
 (TTM)
: 
37.72
?Dividend Yield
 (TTM)
: 
0  ?Payout Ratio
 (TTM)
: 
0
?ROE
 (TTM)
: 
-1.42  ?ROIC
 (TTM)
: 
0.19
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
14.19
?P/B
 (TTM)
: 
83.2  ?Current Ratio
 (TTM)
: 
1.38

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
43.33Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

Based on current fundamentals and analyst forecasts, MARKETSnap estimates SNWV intrinsic value between $6.48 – $6.80 per share. This depends on revenue growth, margins, and discount rate.

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate SNWV Intrinsic Value

Common questions about SNWV valuation

Is SANUWAVE Health, Inc. (SNWV) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for SANUWAVE Health, Inc. (SNWV) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is SNWV a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether SNWV trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is SNWV’s P/E ratio?

You can see SNWV’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for SNWV?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is SNWV a good long-term investment?

Whether SNWV fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

SNWV

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

0.3
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 16.27   Year High: 46.59
Price Avg 50: 23.25   Price Avg 200: 31.27
Volume: 45194   Average Volume: 71562

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
26-03-2026 17:00
Sanuwave Announces Record Revenues and Financial Results for Q4 and Full Year 2025
Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
20-03-2026 13:30
Sanuwave Will Host a Conference Call on March 27, 2026 at 8:30 AM (ET) to Present Q4 and Full Year 2025 Financial Results
09-01-2026 05:00
Sanuwave Health Announces Preliminary Q4 2025 Revenue of $13.3–$13.4 Million, Up 29–30% Year-over-Year; Achieves Record Quarterly and Full-Year Revenue

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read